You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

The Cutting Edge on Cutaneous Malignancies

  • Authors: Laura K. Ferris, MD, PhD; Nicholas J. Golda, MD; David M. Miller, MD, PhD, FAAD; Vishal A. Patel, MD
  • CME / ABIM MOC / CE Released: 5/16/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 5/16/2023
Start Activity


Target Audience and Goal Statement

This activity is intended for dermatologists, primary care physicians (PCPs), nurses, nurse practitioners (NPs), and physician assistants (PAs) involved in the care of patients with cutaneous malignancies.

The goal of this activity is that learners will be better able to manage their patients with cutaneous malignancies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Diagnostic methods for identifying cutaneous malignancies
    • Surgical evaluation of patients with cutaneous malignancies
    • Clinical trial data evaluating treatment regimens for patients with cutaneous malignancies
  • Have greater competence related to
    • Creating customized care plans for patients with cutaneous malignancies
  • Demonstrate greater confidence in their ability to
    • Coordinate with the interdisciplinary and multidisciplinary teams to manage patients with cutaneous malignancies


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Laura K. Ferris, MD, PhD

    Professor of Dermatology
    University of Pittsburgh
    School of Medicine
    Pittsburgh, Pennsylvania

    Disclosures

    Disclosure: Laura K. Ferris, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Arcutis; Bristol Myers Squibb; Cara Therapeutics; Dermavant; DermTech; Janssen; Ortho Dermatologic; Pfizer; Sun Pharma
    Research funding from: AbbVie; Acelyrin; Amgen; Arcutis; Arena; Boehringer Ingelheim; Bristol Myers Squibb; Castle Biosciences; DermTech; Eli Lilly; Galderma; Janssen; Novartis; Pfizer; Regeneron

  • Nicholas J. Golda, MD

    Professor of Dermatology
    MSDO Fellowship Program Director
    University of Missouri School of Medicine
    Columbia, Missouri

    Disclosures

    Disclosure: Nicholas J. Golda, MD, has no relevant financial relationships.

  • David M. Miller, MD, PhD, FAAD

    Co-Director
    NMSC Multidisciplinary Clinic
    Harvard Medical School
    Massachusetts General Hospital
    Boston, Massachusetts

    Disclosures

    Disclosure: David M. Miller, MD, PhD, FAAD, has the following relevant financial relationships:
    Consultant or advisor for: Castle Biosciences; Checkpoint Therapeutics; EMD Serono; Merck KGaA; Merck Sharp & Dohme; Pfizer; Regeneron; Sanofi Genzyme
    Research funding from: Kartos Therapeutics; NeoImmune Tech, Inc.; Regeneron
    Stock options from: Checkpoint Therapeutics
    Owns stock (publicly traded) in: Checkpoint Therapeutics

  • Vishal A. Patel, MD

    Director of Cutaneous Oncology
    GW Cancer Center
    Assistant Professor of Dermatology & Oncology
    George Washington University
    School of Medicine & Health Sciences
    Washington, DC

    Disclosures

    Disclosure: Vishal A. Patel, MD, has the following relevant financial relationships:
    Consultant or advisor for: Almirall; Jounce Therapeutics; PhD Biosciences
    Speaker or member of speakers bureau for: Regeneron; Sanofi
    Stock options from: Lazarus Inc.

Editors

  • Meghan Coulehan, MPH

    Senior Director, Content Development, Medscape, LLC

    Disclosures

    Disclosure: Meghan Coulehan, MPH, has no relevant financial relationships.

  • Briana Betz, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Briana Betz, PhD, has no relevant financial relationships.

  • Faisal Islam, MD, MBA

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Faisal Islam, MD, MBA has no relevant financial relationships.

Compliance Reviewer

  • Esther Nyarko, PharmD

    Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC 

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships. 

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 2.0 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

The Cutting Edge on Cutaneous Malignancies

Authors: Laura K. Ferris, MD, PhD; Nicholas J. Golda, MD; David M. Miller, MD, PhD, FAAD; Vishal A. Patel, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 5/16/2022

Valid for credit through: 5/16/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

The Road Ahead: Updates in the Management of Melanoma

The treatment armamentarium continues to expand
Laura K. Ferris, MD, PhD

Expert Perspectives on Managing Patients With Cutaneous Squamous Cell Carcinoma

Identifying and treating lesions is critical in improving outcomes
Vishal A. Patel, MD

Basal Cell Carcinoma: How to Effectively Manage Your Patients

Are you familiar with the most common human cancer?
David M. Miller, MD, PhD, FAAD

Merkel Cell Carcinoma: Current Concepts in Diagnosis and Management

Don’t let this rare cancer catch you off-guard!
David M. Miller, MD, PhD, FAAD

To Mohs or Not to Mohs? That Is the Question!

Test your Mohs knowledge!
Nicholas J. Golda, MD
 

Educational Impact Challenge

The goal of this activity is that learners will be better able to manage their patients with cutaneous malignancies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print